Source: Circulation. Unidade: FM
Subjects: LIPOPROTEÍNAS, LIPOPROTEÍNAS HDL, INFARTO DO MIOCÁRDIO
ABNT
BONACA, Marc P et al. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation, v. 146, n. 12, p. 907-916, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.122.059325. Acesso em: 02 out. 2024.APA
Bonaca, M. P., Morrow, D. A., Bergmark, B. A., Berg, D. D., Lima, J. A. C., Hoffmann, U., et al. (2022). Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation, 146( 12), 907-916. doi:10.1161/CIRCULATIONAHA.122.059325NLM
Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Nicolau JC. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B [Internet]. Circulation. 2022 ; 146( 12): 907-916.[citado 2024 out. 02 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.122.059325Vancouver
Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Nicolau JC. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B [Internet]. Circulation. 2022 ; 146( 12): 907-916.[citado 2024 out. 02 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.122.059325